NMRA-335140

Phase 3Small molecule

NNeumora Therapeutics, Inc.

NMRA-335140 is one of 53 small molecule programs targeting Bipolar II Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bipolar II DisorderActive, not recruiting

Major Depressive DisorderCompleted

Bipolar II DisorderPhase 2

Active, not recruiting

Major Depressive DisorderPhase 3

Completed

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Daliresp

AstraZeneca

Phase 3

1 2

Latuda

SSunovion Respiratory Development Inc.

Phase 3

3 3

Celebrex

PPhiladelphia Eye Associates

Phase 3

2 4

Bupropion XL

GSK

Phase 3

1 5

ALKS 37

AAlkermes, Inc.

Phase 3

6 6

Desvenlafaxine SR

Pfizer

Phase 3

13 7

Brenipatide

Venlafaxine ER

2 9

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

2 10

Seltorexant

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Effectiveness

NCT06029439

Clinical

Trials by Indication[1]

Major Depressive Disorder4 trials

Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Completed·NNeumora Therapeutics, Inc.·Phase 3·NCT06029426·383 enrolled

Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo

Completed·NNeumora Therapeutics, Inc.·Phase 2·NCT04221230·204 enrolled

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Completed·NNeumora Therapeutics, Inc.·Phase 3·NCT06058013·430 enrolled

Show 1 more trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Completed·NNeumora Therapeutics, Inc.·Phase 3·NCT06058039·422 enrolled

Bipolar II Disorder1 trial

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

Completed·NNeumora Therapeutics, Inc.·Phase 2·NCT06429722·18 enrolled

Effectiveness1 trial

Study to Assess the Safety and Effectiveness of NMRA-335140-501

Recruiting·NNeumora Therapeutics, Inc.·Phase 3·NCT06029439·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for NMRA-335140. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NMRA-335140 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NMRA-335140. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neumora Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNeumora Therapeutics, Inc.

NMRA-335140

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Major Depressive Disorder4 trials

Bipolar II Disorder1 trial

Effectiveness1 trial

References

Drug Info

Quick Facts

Related News